Pamlab, L.L.C., a biomedical company, provides research and development and production services for prescription medical foods to health care providers to address the nutritional requirements of their patients. Its products include Metanx, an orally administered medical food for the dietary management of endothelial dysfunction in patients with diabetic peripheral neuropathy; Deplin, an orally administered medical food for the dietary management of suboptimal folate levels in depressed patients or hyperhomocysteinemia in schizophrenia patients; Neevo and NeevoDHA, which are for the dietary management of impaired metabolic processes in women who face high to intermediate risk pregnancies and ...
4099 Highway 190 East Service
Covington, LA 70433-4941
Founded in 1957
Pamlab, L.L.C. and Breckenridge Pharmaceutical, Inc. Announce Joint Venture to Provide Authorized Generics on Pamlab Branded Medical Food Products
Oct 1 12
Pamlab, L.L.C. and Breckenridge Pharmaceutical, Inc. have entered into a joint venture for the marketing and distribution of authorized generic versions of Pamlab's medical food products containing Metafolin(R). Breckenridge expects to launch the first of these products on October 1, 2012. The joint venture includes a sub-license from Pamlab to Breckenridge for exclusive patents applicable to Pamlab's popular medical foods such as Metanx(R), Deplin(R) and CerefolinNAC(R).
Pamlab, L.L.C.'s Study Indicates Alleviation in Diabetes-Induced Large and Small Fiber Neuropathies in Rats with Prescription Medical Food
Jul 9 12
Pamlab, L.L.C. announced that a study, which demonstrated that dietary management of endothelial dysfunction with Metanx(R) alleviates diabetes-induced large and small fiber neuropathies in rats, was published in the journal Diabetes. The study, conducted by Dr. Irina G. Obrosova and her colleagues from Pennington Biomedical Research Center, utilized Zucker diabetic fatty (ZDF) rats, a model of Type 2 diabetes, to evaluate Metanx(R) on diabetic neuropathy. The study also demonstrated that nutritional management of diabetic peripheral neuropathy with Metanx(R) increased intraepidermal nerve fiber density i.e., promoted small sensory nerve fiber regeneration in the test rats. Diabetic neuropathy is caused by disruption in the natural metabolic processes in blood vessels and peripheral nerve tissues, a common complication of diabetes. In the study, ZDF rats displayed peripheral nerve oxidative stress and diabetic peripheral neuropathy symptoms such as nerve conduction velocity deficit, small sensory fiber dysfunction, and intraepidermal nerve fiber loss. Metanx(R), a medical food, alleviated diabetes-associated sensory nerve conduction velocity deficit and small sensory nerve fiber neuropathy at a body-weight equivalent of human dose. Also, unlike many other experimental therapeutics tested thus far, Metanx(R) induced small sensory fiber regeneration in the rats, potentially due to abrogation of non-enzymatic glycation and oxidative stress.